Magellan Health (MGLN) Tops Q4 EPS by 27c, FY EPS Guidance Comes in LIght

Magellan Health (NASDAQ: MGLN) reported Q4 EPS of $1.24, $0.27 better than the analyst estimate of $0.97. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.83 billion.

GUIDANCE:

Magellan Health sees FY2020 EPS of $3.34-$4.14, versus the consensus of $4.70. Magellan Health sees FY2020 revenue of $7-7.4 billion, versus the consensus of $7.44 billion.

For earnings history and earnings-related data on Magellan Health (MGLN) click here.

You May Also Be Interested In

• Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
• Aardvark Therapeutics (AARD) Tops Q2 EPS by 21c
• Erasca, Inc. (ERAS) Misses Q2 EPS by 3c